ArticleScientific reports2026
Select novel small-molecule uPA potential inhibitors as anti-cancer agents against breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cancer metastasis is a significant contributor to global morbidity and mortality rates. The urokinase type plasminogen activator (uPA) and its receptor (uPAR) play an essential role in facilitating abnormal cell metastasis and tumor progression. This research examines novel uPA/uPAR compounds as potential anticancer targets in various types of tumors. Several compounds were screened for their bioactivity and inhibitory effects on uPA and its receptor interactions, demonstrating the significant potential of a compound previously recognized as a promising uPA inhibitor, initially developed for the treatment of multiple sclerosis. The compounds exhibited notably low IC₅₀ values, as low as 1.4 μM, against the aggressive triple negative breast cancer cell line MDA-MB-231 compared to the chemotherapeutic drug Mitoxantrone. MDA-MB-231 cells treated with KCO241 and KCO246 exhibited selective anticancer activity, inducing apoptotic pathways and demonstrating selective anticancer efficacy. This study showed that these novel uPA inhibitors have potential therapeutic applications for the treatment of metastatic cancers and the modulation of disease progression. Subsequent preclinical in vivo investigations will further evaluate the safety as well as pharmacological characteristics and potential for translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.